# Therapeutic Potential Targeting Gut Microbiota Modulation With Emphasis on Lactobacillus spp. in Common Metabolic Disorders: A Systematic Review

## TL;DR

This review explores how gut microbiota, especially Lactobacillus, can help treat metabolic disorders like obesity and diabetes by improving gut health and reducing inflammation.

## Contribution

The paper systematically reviews the therapeutic potential of gut microbiota modulation, particularly Lactobacillus and SCFA-producing probiotics, in metabolic disorders.

## Key findings

- Gut microbiota dysbiosis is linked to metabolic disorders, and restoring balance may improve health.
- SCFA-producing probiotics and prebiotics show consistent benefits in reducing inflammation and improving metabolism.
- Clinical trials are needed to validate microbiome-based treatments for metabolic diseases.

## Abstract

Metabolic disorders are complex conditions that arise from abnormal biochemical reactions, disrupting normal metabolic processes. The most prevalent metabolic disorders include obesity, Type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), nonalcoholic fatty liver disease (NAFLD), and inflammatory bowel disease (IBD). Despite extensive research, no definitive therapeutic strategy has been established for a complete cure. Emerging evidence suggests that gut microbiome dysbiosis plays a critical role in the pathogenesis of these disorders, as maintaining microbial homeostasis is essential for metabolic health. Short-chain fatty acids (SCFAs) are a key metabolite produced by gut microbiota and exhibit significant therapeutic potential by serving as an energy source for colonocytes, enhancing gut barrier integrity, and modulating inflammation. Our analysis reveals that targeted microbial modulation, particularly through SCFA-producing probiotics and prebiotics, consistently benefits host metabolism and reduces systemic inflammation across multiple conditions. This review highlights the importance of gut microbiota as a viable therapeutic target and underscore the need for further clinical trials to validate microbiome-based interventions in metabolic disease management.